Israel’s Pluristem Therapeutics reported on Wednesday positive outcomes from a series of research in animals of its placenta-based stem cell remedy to treat acute radiation syndrome (ARS).
The research was conducted by the U.S. Division of Defense’s Armed Forces Radiobiology Analysis Institute.
The tests, carried out by the Food and Drug Administration’s (FDA) “animal rule pathway” as ARS can’t be tested in humans, have been designed to evaluate Pluristem’s PLX-R18 as a preventative treatment for ARS prior to radiation exposure.
The research demonstrates that PLX-R18, administered 24 hours prior to radiation exposure and once more 72 hours after exposure, resulted in a rise in survival rates, from 4% in the placebo group to 74% in the handled group, Pluristem stated.
The data further confirmed a rise in the recovery of blood platelets, neutrophils, white blood cells and lymphocytes, and a favorable safety profile. Evaluation of tissues collected showed growth in bone marrow cell numbers and improved regenerative functionality, the corporate said.
“We believe that this outcome is a crucial contribution to protect the armed and medical forces which may enter contaminated regions,” Chief Executive Officer Yaky Yanay mentioned.
“It’s Pluristem’s objective to provide the different national agencies access to PLX-R18 that it could be used as a countermeasure before as well as after radiation exposure with a purpose to reduce hematological and other organ damage.”
PLX-R18 is also being assessed by the National Institute of Allergy and Infectious Ailments, a part of the U.S. National Institutes of Wellbeing, as a remedy following radiation exposure.
In 2018, the FDA allowed the emergency use of Pluristem’s therapy to deal with ARS in a nuclear event.